Pharmacokinetics and pharmacodynamics

Maximizing the clinical potential of erlotinib (Tarceva)

Manuel Hidalgo, Duane Bloedow

Research output: Contribution to journalArticle

Abstract

Pharmacokinetic and pharmacodynamic studies have an important role in the optimization of targeted agents. Phase I pharmacokinetic studies show that treatment with erlotinib HCl (Tarceva; Genentech Inc, South San Francisco, CA), an orally available epidermal growth factor receptor (HER1/EGFR)-tyrosine kinase inhibitor, on a daily, uninterrupted schedule is feasible. Also, plasma drug concentrations, likely to be clinically effective based on preclinical studies, are consistently achieved at the recommended phase II dose of 150 mg/day, the maximum tolerated dose. Pharmacodynamic studies are in progress to assess the activation of HER1/EGFR and associated downstream signaling pathways in tissue samples from patients treated with erlotinib. Expression of p27 is identified as a potential surrogate marker of erlotinib activity, and is a focus of ongoing and future studies. Also, studies indicate that skin may be a useful surrogate tissue for evaluating the pharmacodynamic effects of therapy. These studies will hopefully enable us to accurately assess the extent of target inhibition in patients treated with erlotinib and help optimize its clinical use.

Original languageEnglish (US)
Pages (from-to)25-33
Number of pages9
JournalSeminars in Oncology
Volume30
Issue number3 SUPPL. 7
StatePublished - Jun 2003

Fingerprint

Pharmacokinetics
San Francisco
Maximum Tolerated Dose
Epidermal Growth Factor Receptor
Protein-Tyrosine Kinases
Appointments and Schedules
Biomarkers
Erlotinib Hydrochloride
Skin
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Oncology

Cite this

Pharmacokinetics and pharmacodynamics : Maximizing the clinical potential of erlotinib (Tarceva). / Hidalgo, Manuel; Bloedow, Duane.

In: Seminars in Oncology, Vol. 30, No. 3 SUPPL. 7, 06.2003, p. 25-33.

Research output: Contribution to journalArticle

Hidalgo, Manuel ; Bloedow, Duane. / Pharmacokinetics and pharmacodynamics : Maximizing the clinical potential of erlotinib (Tarceva). In: Seminars in Oncology. 2003 ; Vol. 30, No. 3 SUPPL. 7. pp. 25-33.
@article{ceaede30121b4f33a13ed6d1f99b68c0,
title = "Pharmacokinetics and pharmacodynamics: Maximizing the clinical potential of erlotinib (Tarceva)",
abstract = "Pharmacokinetic and pharmacodynamic studies have an important role in the optimization of targeted agents. Phase I pharmacokinetic studies show that treatment with erlotinib HCl (Tarceva; Genentech Inc, South San Francisco, CA), an orally available epidermal growth factor receptor (HER1/EGFR)-tyrosine kinase inhibitor, on a daily, uninterrupted schedule is feasible. Also, plasma drug concentrations, likely to be clinically effective based on preclinical studies, are consistently achieved at the recommended phase II dose of 150 mg/day, the maximum tolerated dose. Pharmacodynamic studies are in progress to assess the activation of HER1/EGFR and associated downstream signaling pathways in tissue samples from patients treated with erlotinib. Expression of p27 is identified as a potential surrogate marker of erlotinib activity, and is a focus of ongoing and future studies. Also, studies indicate that skin may be a useful surrogate tissue for evaluating the pharmacodynamic effects of therapy. These studies will hopefully enable us to accurately assess the extent of target inhibition in patients treated with erlotinib and help optimize its clinical use.",
author = "Manuel Hidalgo and Duane Bloedow",
year = "2003",
month = "6",
language = "English (US)",
volume = "30",
pages = "25--33",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "3 SUPPL. 7",

}

TY - JOUR

T1 - Pharmacokinetics and pharmacodynamics

T2 - Maximizing the clinical potential of erlotinib (Tarceva)

AU - Hidalgo, Manuel

AU - Bloedow, Duane

PY - 2003/6

Y1 - 2003/6

N2 - Pharmacokinetic and pharmacodynamic studies have an important role in the optimization of targeted agents. Phase I pharmacokinetic studies show that treatment with erlotinib HCl (Tarceva; Genentech Inc, South San Francisco, CA), an orally available epidermal growth factor receptor (HER1/EGFR)-tyrosine kinase inhibitor, on a daily, uninterrupted schedule is feasible. Also, plasma drug concentrations, likely to be clinically effective based on preclinical studies, are consistently achieved at the recommended phase II dose of 150 mg/day, the maximum tolerated dose. Pharmacodynamic studies are in progress to assess the activation of HER1/EGFR and associated downstream signaling pathways in tissue samples from patients treated with erlotinib. Expression of p27 is identified as a potential surrogate marker of erlotinib activity, and is a focus of ongoing and future studies. Also, studies indicate that skin may be a useful surrogate tissue for evaluating the pharmacodynamic effects of therapy. These studies will hopefully enable us to accurately assess the extent of target inhibition in patients treated with erlotinib and help optimize its clinical use.

AB - Pharmacokinetic and pharmacodynamic studies have an important role in the optimization of targeted agents. Phase I pharmacokinetic studies show that treatment with erlotinib HCl (Tarceva; Genentech Inc, South San Francisco, CA), an orally available epidermal growth factor receptor (HER1/EGFR)-tyrosine kinase inhibitor, on a daily, uninterrupted schedule is feasible. Also, plasma drug concentrations, likely to be clinically effective based on preclinical studies, are consistently achieved at the recommended phase II dose of 150 mg/day, the maximum tolerated dose. Pharmacodynamic studies are in progress to assess the activation of HER1/EGFR and associated downstream signaling pathways in tissue samples from patients treated with erlotinib. Expression of p27 is identified as a potential surrogate marker of erlotinib activity, and is a focus of ongoing and future studies. Also, studies indicate that skin may be a useful surrogate tissue for evaluating the pharmacodynamic effects of therapy. These studies will hopefully enable us to accurately assess the extent of target inhibition in patients treated with erlotinib and help optimize its clinical use.

UR - http://www.scopus.com/inward/record.url?scp=0038343126&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038343126&partnerID=8YFLogxK

M3 - Article

VL - 30

SP - 25

EP - 33

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 3 SUPPL. 7

ER -